Dec 30, 2021
We are excited to step into 2022 together with IBF
Proud to be part of exclusive portfolio of innovative #lifesciences companies.
This funding accelerates the path towards clinical stage of our first-in-class biotherapy targeting cancers with p53 mutations.
We are on mission to bring cure to cancer patients.